Given the patient's long-standing history of psoriasis and the current flare, we diagnosed a transition from psoriasis vulgaris toward pustular psoriasis. After discussing treatment options with the patient, including IL-17 inhibitors, IL-23 inhibitors, and deucravacitinib, he expressed a preference to begin with the medication associated with the lowest risk of adverse effects, given his underlying MDS. This evidence concerns the gene IL17A and psoriasis.